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ABSTRACT: Antimicrobial resistance stimulates the
search for antimicrobial forms that may be less subject to
acquired resistance. Here we report a conceptual design of
protein pseudocapsids exhibiting a broad spectrum of
antimicrobial activities. Unlike conventional antibiotics,
these agents are effective against phenotypic bacterial
variants, while clearing “superbugs” in vivo without toxicity.
The design adopts an icosahedral architecture that is
polymorphic in size, but not in shape, and that is available
in both L and D epimeric forms. Using a combination of
nanoscale and single-cell imaging we demonstrate that such
pseudocapsids inflict rapid and irreparable damage to bacterial cells. In phospholipid membranes they rapidly convert
into nanopores, which remain confined to the binding positions of individual pseudocapsids. This mechanism ensures
precisely delivered influxes of high antimicrobial doses, rendering the design a versatile platform for engineering
structurally diverse and functionally persistent antimicrobial agents.
KEYWORDS: protein design, antimicrobial resistance, artificial pseudocapsids, persister cells, superbugs, nanopores
With conventional antibiotics losing effectivity at analarming rate,1 antimicrobial resistance represents amajor health threat.2 This challenge stimulates the
search for more effective antimicrobial forms that may be
different from traditional antibiotics altogether.3 Most anti-
biotics act by binding to individual intracellular targets in
bacterial cells. A single genetic event is enough for bacteria to
acquire resistance.3 As a consequence, bacteria develop into
“superbugs”, strains that no longer respond to antibiotic
treatments. The spread of these pathogens can be counteracted
by antimicrobials tackling a bacterial cell as a whole, thus
demonstrating potential to kill growing, persister, and dormant
cells, the feat that is inaccessible to conventional antibiotics.4
The innate immune systems of multicellular organisms do not
use antibiotics. Instead, they deploy host-defense effector
molecules to the sites of infection. These molecules are stand-
alone peptides or relatively small domains in globular proteins
that recognize microbial surfaces.5 These molecules are diverse
in structure and origin but share common physicochemical
properties. Most of them are cationic and fold into
amphipathic conformations upon binding to anionic microbial
membranes.6 In membranes, these conformations assemble
into higher-order oligomers that overcome a threshold of
peptide concentration, beyond which antimicrobial effects
become apparent.7 This is more characteristic of host-defense
peptides8 than of effector domains of multifunctional proteins
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that recognize pathogen surfaces without the need to self-
oligomerize.9 Yet, in free forms these domains can oligomerize
to induce bacteriostatic effects.10 This distinction presents a
considerable opportunity for antimicrobial engineering. In
principle, multiple copies of an effector domain can be
arranged to fold into a discrete assembly,11 which upon contact
with microbial membranes would instantaneously deliver
peptide concentrations that significantly exceed those neces-
sary to rupture microbial membranes. An ultimate benefit of
such an agent is rapid and irreparable damage to a microbial
cell without the need for the transition from unstructured
monomers to membrane-active oligomers. As a result, this
agent may be equally effective against susceptible, resistant,
and persister cells, thus providing a foundation for antibacterial
persisters: nanoscale agents whose activity is not subject to
bacterial phenotypes and acquired resistance. However, the
success of this strategy relies on addressing the following
principles.
Since bacteria are 0.2−1 μm in width, an assembly of tens of
nanometers in diameter would inflict irreparable damage to a
bacterial cell. To be discrete at these size ranges, the assembly
is best confined to a platonic, symmetrical structure. The
nature of the symmetry is of less importance as long as the
assembly is locked into a three-dimensional form that is able to
bind to microbial membranes. In this regard, viral capsids
inspire a straightforward solution. These are self-assembled
nanoscale protein cages or cages that do not kill bacteria on
contact but provide suitable architectural templates for capsid-
like assemblies of effector molecules. The antimicrobial
function of the resulting structures permits structural poly-
morphism that is typical of aberrant and pseudocapsids.12−14
Furthermore, it also imposes no a priori constraints on the
chirality of the effector domains. Polypeptide chains of
reversed chirality, i.e., all-D peptides, are far more stable to
proteolysis, fold in a similar manner to that of all-L peptides,
and are likely to be nonimmunogenic.15−18 Antimicrobial D
epimers are as effective as their L counterparts, which is
consistent with the fact that host-defense peptides act by
binding to the lipid components of bacterial membranes rather
than docking to a specific protein.18,19 Herein we apply the
outlined principles for the design of antimicrobial pseudocap-
sids or Ψ-capsids and demonstrate that such assemblies stand
out among artificial and native particulate structures by being
biologically persistent agents in vitro and in vivo, delivering
nanoprecise antimicrobial effects that do not depend on
chirality, with both their L- and D-forms exhibiting comparable
activities.
RESULTS
Pseudocapsid Design. Our approach adapts a short host-
defense motif from a multifunctional protein lactoferrin, a
major component of the innate immune system.9,10 The
antimicrobial properties of this protein are attributed to its N-
terminal domain. The domain has a broad spectrum of targets
including porins, DNA, and intracellular metabolites and can
stimulate the immune system by neutralizing endotoxin.20−22
The host-defense motif of the domain is a hexapeptide
RRWQWR, which has strong propensity for antiparallel β-
sheet conformations.23
To render this motif self-complementary, the C-terminal
arginine of the peptide was replaced with a glutamate. This
modification facilitates interstrand Coulombic interactions
with the N-terminal arginine of the opposite β-strand. The
core of the motif is also homologous to a characteristic motif of
tryptophan zippers, WTW, which folds with cross-strand
tryptophan rings packed tightly against one another.24 To
capitalize on this analogy, the glutamine in the peptide was
replaced with a threonyl residue. This modification supports
the formation of a tryptophanyl interface to cement a β-sheet
bilayer with two cationic exteriors. In viruses, capsid proteins
interface orthogonally with each other to network into penta-
and hexagonal assembly units. Each of these units adopts a 3-
fold rotational symmetry, which ensures their propagation into
a closed, spheroid symmetry.25 To emulate the 3-fold
symmetry of native cage-like subunits, the resulting monomeric
peptide RRWTWE was converted into a triskel conjugate
Figure 1. Pseudocapsid design. (A) Molecular model of the triskel RRWTWE conjugate. (B) Snapshot of molecular dynamics simulations
showing a pentagonal assembly unit formed by designed triskelions. (C) Two β-sheet arms (green and yellow) forming a bilayer interface via
cross-strand packed tryptophans (gray). (D) Schematic representation of the designed triskelion as a monomer subunit in a truncated
icosahedron shown as a 5-fold Schlegel orthographic projection. (E) Five-fold symmetry orthographic projections of two truncated
icosahedra (black and red) forming a double-walled assembly. Note: for clarity only one of each of the pentagonal (green) and hexagonal
(orange) units is highlighted in (D) and (E). (F) Single-walled triskelion assembly templated on a truncated icosahedron. (G) Double-walled
triskelion assembly templated on a truncated icosahedron. Outer and inner layers in (F) and (G) are shown in green and yellow,
respectively.
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(Figures 1A and S1 in Supporting Information), with both L-
and D-forms of this conjugate chemically synthesized (Figure
S2). Each arm of this triskelion pairs in an antiparallel β-sheet
with another arm of another triskelion. Each folded pair of two
arms interfaces with another folded pair of two other
conjugates (Figure 1B,C). The monomer has a trilateral
symmetry, which enables it to assemble into penta- and
hexagonal units forming β-sheet bilayer networks (Figure 1B).
Because β-strands are stabilized by interstrand interactions, it
is physically impossible for the bilayers to have free, “sticky”
edges. These have to close on one another. Triskelion
structures have an intrinsic nonzero curvature.26,27 In
propagating β-sheet networks, the curvature translates into a
trans-sheet asymmetry, prompting the spontaneous closure of
increasingly curved sheets into a minimum energy sphe-
roid.11,28 This mode of assembly is analogous to that of viral
particles, which follows an icosahedral symmetry, with a
truncated icosahedron being one of the most common
architectures.29,30 This polygon architecture offers an ideal
template for the assembly of triskelions: it has only 3-fold
vertices, each of which can host an individual triskelion (Figure
1D,E). Therefore, if triskelions fold cooperatively within the
template, the propagating β-sheet networks should self-close
into an equilibrated and discrete structure. The monolayer
configuration of this structure is not stable, as the hydrophobic
side chains of the tryptophanyl residues are oriented inward
toward its water-filled core (Figure 1F). A β-sheet bilayer or a
double-wall β-sheet, in which cationic arginyl residues furnish
its exterior and interior surfaces, is deemed more stable (Figure
1C,G).31 In support of this conjecture, coarse grain molecular
dynamics (MD) simulations32 showed that single-wall
icosahedra assembled from the triskelion collapsed within the
first 600 ns of simulations following an equilibration phase
(Figure S3A). Under the same simulation conditions, double-
Figure 2. Pseudocapsid assembly. (A) TEM images of assembled D-Ψ-capsids. Scale bars are 50 nm. (B) Higher resolution TEM images of
individual collapsed negatively (upper) and positively (lower) stained capsids. Scale bars are 50 nm. (C) Topography images of D-Ψ-capsids
obtained on a mica substrate by AFM in liquid. Color (height) and scale bars are 60 and 200 nm, respectively. (D) 3D representation of D-Ψ-
capsids. Color (height) bar is 50 nm. (E) Size distributions and dominating sizes of D-Ψ-capsids by AFM and TEM. Error bars denote
standard deviations. (F) Average sizes of dominating populations of Ψ-capsids. Assembly conditions: 100 μM peptide, pH 7.4, 10 mM
MOPS, 20 °C, overnight (15 h).
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walled structures retained their initial configuration over 1 μs
of coarse grain simulations, evolving into more compact
shapes, for both L- and D-forms, which was also confirmed by
100 ns atomistic simulations33 (Figure S3B,C and Movie S1).
Further simulations confirmed that the double bilayer
maintained β-sheet networks intact, while allowing individual
β-strand pairs to break and re-engage in the outer layer. This
ability of β-sheets to rearrange without compromising the
stability of the assembly renders changes in the networks
cooperative and suggests that triskelions can indeed assemble
cooperatively in the template, which should manifest in the
formation of an equilibrated, discrete, and stable structure
(Figure S4).
Pseudocapsid Folding and Assembly. Consistent with
the simulations, circular dichroism (CD) spectra for both
forms of the triskelion were characteristic of antiparallel β-
sheet and β-turn conformations (Figure S5A). Fourier
transform infrared (FT-IR) spectra revealed bands for the
deconvoluted amide regions at 1650−1670 cm−1 for β-turn
structures and at 1630 and 1545 cm−1 for β-sheets (Figure
S5B). These results suggest that inter- and intramolecular
hydrogen bonds in β-sheets and β-turns, respectively, support
the cooperative folding of the triskelions into higher-order
structures.
Indeed, transmission electron microscopy (TEM) and
atomic force microscopy (AFM), performed in solution,
revealed uniformly spherical capsids (Figure 2A−D). Some
of these appeared as collapsed or open structures giving a
double-walled or double-layered morphology (Figure 2B).
Negatively and positively stained capsids gave darker and
lighter interiors, respectively, due to stain accumulation. This is
characteristic of synthetic virus-like and native virus structures
(Figure S6).34,35 An enclosing boundary was also apparent,
suggesting a space between the two layers (Figure 2B). Since
most of the assemblies remained as dense spheroids (Figure
2A), we sought further evidence for the hollow nature of the
assembled structures and probed their mechanical properties
directly in solution by local nanoindentation with simultaneous
topographic imaging (Figure S7). By mapping the effective
elastic modulus of the capsids as a function of position on the
assembled capsids,36 it was found that the capsids were
seemingly compliant at their edges. This is expected since the
capsids can move sideways in response to the vertically
indenting AFM tip. More importantly, however, the capsids
were appreciably more compliant to indentation at their
centers, compared with surrounding areas. These results, which
were consistent across all capsid sizes observed, are indicative
of hollow spheroids (Figure S7). The diameters of the
spheroids themselves were comparable by both width
(TEM) and height (AFM) measurements and were dominated
by a narrow size range of 20−40 nm (Figure 2E,F). An
overlapping range of 10−20 nm was also evident, particularly
by height measurements. Since these measurements are
performed in solution and without staining, unlike TEM, the
results exclude dehydration effects and contributions from
stains, which may explain a lesser distinction between particle
sizes observed by TEM (Figure 2E,F). The lower size range
was half the size of the first one, suggesting that the triskelions
may adopt an integer step size in assembly, generating
structures that are polymorphic in size but not in shape. The
assembled capsids remained in the same two diameter ranges
at micro-to-millimolar peptide concentrations; that is, they
were not concentration dependent (Figure S8A). The
assembly was also complete in the first 2 h of incubation
and did not deviate significantly from the size ranges over 15 h
(Figure S8B). In good agreement with the simulation data
(Figures 1 and S3), these results support a cooperatively
assembled, stable structure. As expected, the monomeric
peptide, which has no capacity to propagate, did not assemble
even at high concentrations (Figure S9). This ability of the
designed Ψ-capsids to accommodate different sizes is akin to
that of viral capsids and synthetic virus-like assemblies that can
adapt to repack into smaller and larger particles.37−39 This is
also in marked contrast to mutant viral capsids and
polymorphic virus-like particles, whose variations in morphol-
ogy feature filamentous and aberrant structures with irregular
serrations.13,14
The designed triskelions are asymmetric dendritic hubs with
three peptide arms folding into equivalent β-strands (Figure
S1). The asymmetry of each hub incorporates reciprocally into
the trans-sheet asymmetry of propagating β-sheet networks.
This contribution is additional to the intrinsic curvature of
triskelions and helps them adjust to geometric variations in
local environments. Turn structures that separate the peptide
arms in hubs ensure the three-directional assembly of
triskelions without sterically occluding the pairing of peptide
arms. These features are complementary to one another and
promote C3 rotational symmetry, enhancing local symmetry
interactions in a cooperative manner that is similar to that of
native viruses40 and virus-derived systems.34 In particular,
capsid proteins, which are asymmetric, form quasi 3-fold
contacts to set up identical polygonal subunits that occupy
different geometric environments.41 This is sufficient for
relatively small (T < 4, where T is a triangulation number)
viruses.25 Larger capsids are enabled by incorporating large or
scaffolding proteins that serve as an inner core on which the
capsid assembly can be templated.42 Scaffolding proteins for
the designed pseudocapsids are not necessary, as the β-sheet
networks arrange into bilayers stabilized by hydrophobic
interfaces. These interfaces keep the assembly intact and rectify
the impact of broken β-sheet contacts in the networks through
cooperative rearrangements,39 i.e., acting as inner templates or
cores. This agrees well with the results of MD simulations that
showed that such rearrangements take place in the outer part
of the bilayer. The hydrophobic face of the inner layer that
seeds the interface appears to partially destabilize β-sheet
networks in the outer layer, making them concomitant or
“fluid”. In contrast, the inner layer itself remains intact in all of
its constituent β-sheets (Figure S4). This property extends to
the ability of the triskelions to adapt to size variations in the
assembly. Indeed, course grained, optimized assembly
simulations of double-wall networks confirmed that the
triskelions can readily accommodate the size ranges observed
experimentally (Figures 2 and S10).
Taken together the findings indicate that the designed
triskelions propagate with the formation of thermodynamically
stable Ψ-capsids exhibiting a degree of structural plasticity that
helps accommodate size variations without compromising on
morphological uniformity. Since the triskelions occupy the
vertices of pentagonal and hexagonal faces in the truncated
icosahedron, rather than tightly pack in the faces, the overall
architecture of Ψ-capsids remains independent of size allowing
for wide size variations. This property renders the assembly
adaptable to morphological changes imposed by hierarchically
complex and dynamic environments such as microbial
membranes.
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To test their behavior in membranes in sufficient detail, Ψ-
capsids were introduced into reconstituted phospholipid
bilayers that were assembled on mica substrates as described
elsewhere.43 The resulting supported lipid bilayers (SLBs)
provide suitable models for bacterial membranes, are flat (to
within ∼0.1 nm) in their unperturbed state (Figure 3A,B), and
allow for the accurate depth measurements of surface changes
in solution and in real time by AFM.44 As gauged by these
measurements, Ψ-capsids bound to the SLBs and disintegrated
on them forming pore- and channel-like lesions (Figure 3A−
C).
The conversion of individual assemblies into pores at their
precise binding positions was complete within a few minutes of
treatment: Ψ-capsids gradually sank in the lipid bilayers at the
depths of a folded triskelion arm, ∼1.8 nm (0.3 nm translation
per β-strand residues) (Figure 3A−D). Coarse grain
simulations of the capsids in the lipid bilayers45 run over 10
μs revealed that the sinking effect occurred at the expense of
pressing and displacing lipids deep into the bilayer interface
(Figure 3E, Movie S2). In accord with this, atomistic
simulations of a rudimentary pore showed that triskelion
arms oriented toward the bilayer interface (Figures 3F and S11
and Movie S3). Such localized responses are consistent with a
mechanism where triskelions reassemble in the bilayer and that
forming pores do not expand and remain confined within the
diameters of Ψ-capsids. This is important for three reasons.
Figure 3. Pseudocapsids porating phospholipid bilayers. (A) In liquid AFM topography of SLBs treated with D/Ψ-capsids. The images are
taken at 4 min intervals. Individual Ψ-capsids are numbered (1−6) to highlight conversions into pores. Scale bars are 100 nm for the first
image and 200 nm for the others. The height (color) bar is 10 nm. (B) Cross-sectional analyses of Ψ-capsids numbered as in (A) for each
given time point. (C) Topography of a Ψ-capsid converting into a pore in 15 min, with the height profiles of the corresponding conversion
area. Images are taken at 5 min intervals. Scale and height (color) bars are 50 and 10 nm, respectively. (D) Plot combining height profiles of
threeΨ-capsids from (A) to show conversions as a function of time. (E) Snapshot of coarse-grain MD simulations of a Ψ-capsid binding to a
phospholipid bilayer at 2 μs and simulated for an additional 8 μs. Key: outer and inner layers of the β-sheet bilayer are in green and yellow,
respectively; golden beads denote phosphate groups linked to two types of polar groups (blue and magenta); aliphatic lipid tails are in cyan.
(F) Snapshot of a rudimentary pore showing a triskelion arm stretching across the bilayer interface after 72 ns of a 100 ns atomistic
simulation. Key: for clarity, only phosphate groups (golden beads) are shown for the bilayer.
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First of all, the assemblies exhibit a larger structural plasticity
than crystalline materials or viruses do, which allows them to
rapidly rearrange into peptide−lipid oligomers at the sites of
contact with phospholipid membranes. Second, these
oligomers maintain the size of the resulting pores close to
that of the landed capsids, thereby supporting precise and site-
specific membrane disruption. Third, this behavior suggests
that Ψ-capsids may support differential responses in cell
environments favoring attack on microbial membranes. To
gain a better insight into this, the biological properties of Ψ-
capsids were assessed using a range of in vitro and in vivo
assays.
Biological Properties of Pseudocapsids. Irrespective of
chirality, Ψ-capsids were found to be antimicrobial and
nonhemolytic (Table S1). The minimum inhibitory concen-
trations (MICs) of the capsids were comparable to those of
antimicrobial agents including conventional antibiotics (Table
S1). The monomeric peptide remained inactive at up to 100 ×
MICs of the capsids (>100 μM) against all bacteria tested.
However, the principal advantage of Ψ-capsids over anti-
microbial compounds lies in their ability to exert rapid and
irreparable damage to a bacterial cell, which makes them
equally effective against susceptible cells and cells that are
tolerant to conventional antibiotics. In liquid AFM experi-
ments showed that the capsids can indeed disrupt membranes
within minutes. MIC experiments cannot directly relate to the
AFM results, as these are optical density measurements that do
not consider changes at the cellular level. Therefore, we sought
Figure 4. Single-cell antimicrobial kinetics of pseudocapsids. (A) Three panels of representative optical micrographs of E. coli cells (i) killed
by D/Ψ-capsids; (ii) survived and regrown after ampicillin treatments (persister cells); (iii) survived but not regrown after ampicillin
treatments (VBNC cells). In each panel, image bars show (from left to right) cells after 3 h treatments with capsids or ampicillin, during
subsequent washing with the growth medium over 21 h, and after washing. The last micrographs in the panels are fluorescence images of 24
h samples stained with propidium iodide (PI), a live−dead stain penetrating dead bacteria with compromised membranes. (B) Cell fractions
treated with D/Ψ-capsids and ampicillin. The data and error bars are means and standard error of the means of measurements obtained for
3332 cells hosted in 2331 independent microfluidic channels in four independent biological replicates. The distribution of fractions of
susceptible cells to ampicillin was significantly lower than that to D/Ψ-capsids (p < 0.0001). The distributions of fractions of persister and
VBNC cells to ampicillin were significantly higher than those to D/Ψ-capsids (p < 0.0001). (C) Electron micrographs of microtomed E. coli
cells before treatment with D/Ψ-capsids. The scale bar is 200 nm. (D) Electron micrographs of microtomed E. coli cells after treatment with
D/Ψ-capsids. The scale bars are 200 nm.
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complementary evidence from three series of experiments
using planktonic and sessile bacterial culture of two of the most
common pathogens, E. coli and S. aureus. In the first series, the
antimicrobial activity of Ψ-capsids was assessed as a measure of
total cell counts following capsid treatments.11 Negligible cell
counts were observed for cultures treated with the capsids in
comparison to the samples of untreated cells in which
appreciable bacterial growth was observed (Figure S12).
These findings provide end-point results of treated cell
populations obtained over the same time scale as MIC
measurements. To elucidate the antimicrobial kinetics of Ψ-
capsids within the first hours and with a single-cell resolution,
the second series of experiments was conducted. In these
experiments thousands of individual E. coli cells were screened
using a high-throughput microfluidic device comprising
thousands of growth channels.46 Each channel serves as a
trap for an individual cell where the cell can grow through one
of its distal poles, whereas the diameter of the channel matches
that of the cell, thereby arresting its movement.47 The
replicative age of this trapped, mother, cell increases by one
generation at each cell division, allowing to follow phenotypic
cell inheritance for an infinite number of generations. Such a
“mother machine” then enables the single-cell monitoring of
antimicrobial kinetics in situ and is able to reflect the responses
of different cell phenotypes to antimicrobial agents.48 With this
in mind, Ψ-capsids were introduced into E. coli cells trapped in
the channels of the device (Figure 4A).
After 3 h of treatment under a constant flow the microfluidic
environment was replaced by flowing the culture medium over
21 h to restore normal conditions for bacterial growth.
Subsequent analyses revealed that Ψ-capsids killed all
encountered cells (Figure 4). By contrast, persister cells and
viable but not-culturable (VBNC) cells were found after
ampicillin treatments (Figure 4A,B). These tolerant pheno-
types represent common subpopulations in clonal bacterial
cultures that persist antibiotic treatments even at high doses.49
Persister cells resume growth after the drug is removed from
their environment, whereas the regrowth of VBNC cells often
requires specific conditions.50,51 Both phenotypes contribute to
infection relapses, prompting repetitive treatments, and can be
linked to dormancy.52 With Ψ-capsids effectively reducing
these phenotypes to susceptible cells, changes in cell
morphology may shed light on the mechanism of action at
the single-cell level. Indeed, the capsid-treated cells appeared
shrunk and somewhat denser when compared to unaffected
cells, suggesting that the capsids accumulated in the
membranes. This is consistent with the AFM results (Figure
3), although the cells in the mother machine did not
disintegrate and seemed intact (Figure 4B). Therefore, cells
treated with capsids were microtomed and imaged by TEM
(Figure 4C,D). Complete membrane destruction was evident
(Figure 4D). Intriguingly, however, many cells appeared as
empty and half-empty, having displaced and bulging
membranes that tended to open up at distal poles (Figure
4D). This effect is not normally observed for bacteria damaged
by host-defense peptides or membrane-active antibiotics,
which porate bacterial membranes indiscriminately, causing
cells to shrink and leak43 or, as polymyxins, aggregate with
lipopolysaccharides into membrane-destabilizing blebs across
the whole bacterial surface.53 The emphasis on distal poles is
reminiscent of bacteriophages that preferentially target the
poles of bacterial cells.54 Although, like polymyxins, Ψ-capsids
favor anionic lipids, morphologically they are more of phage
mimetics that may be attracted to outward membrane
curvature or cell poles serving as DNA mobilization sites
before cell division.54,55 The third series of experiments
provided further insight into this. The attack of Ψ-capsids on
E. coli cells was monitored by structured illumination
microscopy (SIM), which was custom designed to image
biomolecular and cellular processes in situ.56−58
The capsids rapidly adhered to the cell surfaces, with
adsorption at the distal poles being also apparent (Figure 5A).
Within a doubling time (20 min), the capsids proved to come
into direct contact with the cells accumulating in their
Figure 5. Time−kill kinetics of pseudocapsids in vitro. Structured illumination micrographs of E. coli cells (A) immediately after the addition
of L/Ψ-capsids and (B) during the treatment highlighting individual capsids in contact with cells. The capsids are labeled with
carboxyfluorescein (green). Cell membranes are stained with FM4-64FX (red). Scale bars are 5 μm and 500 nm for (A) and (B),
respectively. (C) SIM images recorded at 5 min intervals for E. coli (upper) and S. aureus (lower) with and without the Ψ-capsids. Scale bars
are 1 μm. (D) SIM images of E. coli cells at 45 min of treatment with carboxyfluorescein-labeled L/Ψ-capsids.
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membranes and cytoplasm (Figure 5B,C). The affected cells
then underwent sharp rupture accompanied by a burst of
fluorescence intensity (Figure 5C and Movie S4). This effect
was more profound in cocci cells (S. aureus). Although the
distal poles of these cells are less defined, the transition from
the initial contact with Ψ-capsids to the disintegration of their
only membrane was somewhat sharper when compared to that
for E. coli (Figure 5C and Movie S5). The killing for both
bacteria was complete within 45 min (Figure 5D and Movies
S4 and S5), while the time of cell disruption closely matched
that needed for the conversion of the capsids into membrane-
disrupting pores as gauged by AFM (Figure 3). Collectively,
these findings suggest that Ψ-capsids need not disintegrate in
the membranes, which they may effectively traverse reaching
the protoplasm. Such a mode of action infers that the capsids
may be able to circulate intact in cellular environments that are
challenged by sustained and active bacterial growth.
To verify this in a biologically relevant model, Ψ-capsids
were administered into G. mellonella larvae infected with a
methicillin-resistant S. aureus (MRSA) strain susceptible to
vancomycin.59,60 Over the first 48 h the treatments were as
effective as those by high doses of vancomycin (Figure 6A).
The survival rate of up to 80% proved to be steady for another
24 h for larvae treated with D/Ψ-capsids, whereas a 10% drop
was observed for larvae treated with the L-form (Figure 6A).
The resulting rate of 70% did not change over the total of 120
h of treatment for L/Ψ-capsids. In comparison, for the D-form
it dropped to 50% on day 4, suggesting a depletion of the
capsids in the larvae. The exact reason for this is unclear,
although the decrease is likely to link to the fact that D/Ψ-
capsids were more active during the first 72 h, possibly at the
expense of more capsids being engaged with bacteria (Figure
6A).
The observed survival rates of the larvae proved to be
superior over those reported for membrane-active antibiotics
and bacteriocins, indicating that the capsids may be equally
effective in killing bacterial cells from the outside and
inside.60,61 These experiments also demonstrate the impor-
tance of preassembling effector monomers into the pseudo-
capsids. In particular, they provide evidence for the
pseudocapsid assembly enabling prolonged antimicrobial
effects. This is further emphasized by the failure of stand-
alone host-defense peptides to exert any effects under the same
conditions. For instance, the administration of strongly
bactericidal human (LL37), insect (cecropin B), and animal
(magainin 2) antimicrobial peptides into the infected larvae
did not improve survival rates relative to those of mock
injections with PBS (Figure 6A). Partly, this failure can be
attributed to the enzymatic instability of the nonassembling
peptides in vivo. However, both L- and D-forms of the
pseudocapsids were similarly effective, which points out that
it is the capsid assembly itself that determines the sustained
antimicrobial activity. Furthermore, the capsids maintained
high rates of bacterial clearance even when administered at
Figure 6. Time−kill kinetics of pseudocapsids in vivo. (A) Survival of G. mellonella larvae infected with vancomycin-susceptible MRSA
NCTC12493 strain when treated with Ψ-capsids and host-defense peptides. Vancomycin and phosphate-buffered saline (PBS) were used as
positive and negative controls, respectively. Inoculations were done straight after the initiation of infection (first 2 h) without subsequent
treatments. (B) Survival of MRSA-infected G. mellonella larvae treated with vancomycin, L/Ψ-capsids, and PBS, administered at 18 and 36 h
after the initiation of infection. Survival rates for Ψ-capsids were significantly higher when compared to PBS control (Mantel−Cox test, p <
0.001). Gray arrows indicate inoculation time points. (C) Survival of G. mellonella larvae treated with Ψ-capsids. Inoculations were done
straight after the initiation of infection (first 2 h) with two subsequent treatments at 24 and 48 h.
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significantly delayed injection times: the larvae treated with
capsids at 18 and 36 h exhibited a 50% survival up to day 4
postinfection (Figure 6B), which is twice the time achieved by
bacteriophage therapies.62 Finally, multiple injections of the
capsids into uninfected larvae did not lead to appreciable
cytotoxic effects (Figure 6C).
CONCLUSIONS
We have demonstrated that discrete pseudocapsids assembled
from effector molecules deliver rapid and irreparable damage
to bacterial cells. The damage results from a direct impact that
such assemblies have on cells and ensues via multiple avenues
starting with the rapid conversion of the pseudocapsids into
membrane-disrupting pores. Pore formation is spatially
confined to the binding position of a pseudocapsid, which
ensures the rapid and highly localized influx of high
antimicrobial doses at the site of contact. Such an impact is
different from that of organic or inorganic nanoparticles that
rupture membranes indiscriminately by a purely physical
means, are unable to disintegrate, and are prone to
agglomeration. In contrast, the protein pseudocapsids are
cooperative ensembles of monomeric units that reassemble in
membranes and integrate into the protoplasm. Thus, these
ensembles are equilibrated, symmetry-driven nanoscale sys-
tems, which is a prerequisite if they are to remain autonomous
within the set size range.25,63,64 The polygonal architecture of
viral capsids proved to be a suitable framework for templating
the assembly of monomeric units, which can be of virtually any
chirality and topology. The framework is compatible with the
double-layered arrangement of β-sheet networks that are
stabilized by hydrophobic interfaces running tangentially to the
capsid surface. Apart from the cases of scaffolding proteins,
viral capsids employ single-layered β-pleated networks in this
orientation (e.g., rhino- or poliovirus), which are typically built
of closed β-barrel structures.65 To this end, in synthetic
peptide and protein cages such networks have been viewed as
single-layered structures.11,39
An efficient strategy for the design is to repurpose host-
defense effector molecules into structurally and functionally
tunable motifs that are furnished with the ability to rapidly self-
assemble. Individually, both monomeric units and the motifs
may resemble membrane-active antibiotics, but their efficacy is
no longer subject to the lag phase of reaching a critical
threshold concentration on bacterial surfaces. Once assembled
into a discrete pseudocapsid, the constituent monomers
acquire a dual capacity of preconcentrated and stimuli-
responsive antimicrobial doses. This preassembly of the
monomers defines the ability of the capsids to differentiate
between bacteria and erythrocytes. With the surfaces of red
blood cells being weakly anionic, strong antimicrobial activities
often carry an additional cost of hemolytic effects, which is
common for toxin or venomous peptides such as bacteriocins
or melittins (Table S1). The designed pseudocapsids are
different in that they assemble from peptide monomers that
individually are not antimicrobial but have an inherent ability
to bind to microbial membranes. Therefore, the capsids
themselves are antimicrobial agents that exert their activity
through highly localized disruption of microbial membranes,
accompanied by the conversion of the capsids into pores. Since
the capsids did not lyse erythrocytes and were not cytotoxic in
vivo, the mechanism supports the differential activity of the
design. This biological responsiveness builds upon the
structural plasticity of the capsids,11,66 and, subsequently,
requirements for nanoscale order are looser than those for viral
subunits that tune their assembly to the size of encapsidated
genomes. Like other paracrystals, which often exhibit periodic
nanoscale patterns (e.g., striations or rings),67,68 the designed
pseudocapsids display fine surface structure (Figure 2A−D).
Although this did not feature readily recognizable patterns, the
assemblies appeared to adopt a size integer and were
monomorphic in shape, lacking competing morphologies
such as filaments.69 Combined, these properties represent a
highly effective antimicrobial system that, unlike antibiotics, is
not frustrated by antibiotic-tolerant phenotypes, such as
persister or VBNC cells, or by “superbugs” such as MRSA,
killing all. This outcome is notable in that the design may
provide a useful tool to aid in a better understanding of how
different bacteria phenotypes can be distinguished and
selectively targeted.70
A question remains as to how universal pseudocapsids are in
overcoming different resistance mechanisms including cell
surface fortifications, efflux pump blockages, or peptide
antagonists that block access to cell membranes.71−74 As it
has been long postulated75 and re-emphasized recently,76 host-
defense polypeptides are evolutionarily conserved molecules,
against which a widespread resistance cannot be developed
easily. Resistance mechanisms against them exist but are not
deemed systemic and are readily counteracted by relatively
marginal alternations in peptide structure.76,77 In this light, the
pseudocapsids introduced here may constitute a step change in
the applied chemistry of host-defense effector molecules
shifting the host−pathogen arms race in favor of more
sustainable and adaptable antimicrobial treatments, serving
an ultimate pursuit of reducing the spread of antimicrobial
resistance.
METHODS
Peptide Synthesis and Purification. L- and D-Triske-
lions(RRWTWE)-βA-K(RRWTWE)-K(RRWTWE)-amwere as-
sembled on a Liberty microwave peptide synthesizer (CEM) using
standard Fmoc/tBu solid-phase protocols with HBTU/DIPEA as
coupling reagents on a Rink amide MBHA resin. Fmoc-K(Mtt)−OH
was used to enable orthogonal conjugation via a trifunctional
dendritic hub, βAKK-am. Carboxyfluorescein-labeled triskelions
were made on resin by coupling carboxyfluorescein to the N-terminus
of βA-RRWTWE-βAKK, with fully protected side chains, on the resin.
The remaining two arms were then assembled on resin following Mtt
removal. Magainin 2 and cecropin B were synthesized as peptide
amides on a Rink amide MBHA resin, and LL37 was assembled as a
peptide acid on an Fmoc-S(tBu)-Wang resin. After postsynthesis
cleavage and deprotection (95% TFA, 2.5% TIS, 2.5% water) all
peptides were purified by semipreparative reversed-phase high-
performance liquid chromatography (RP-HPLC). Peptide identities
were confirmed by analytical RP-HPLC and MALDI-ToF.
MS [M + H]+: cecropin B, m/z 3834.6 (calc), 3836.0 (found);
LL37, m/z 4493.2 (calc), 4495.8 (found); magainin 2, m/z 2465.9
(calc), 2467.0 (found); L-triskelion, m/z 3090.5 (calc), 3092.3
(found); D-triskelion, m/z 3090.5 (calc), 3092.8 (found); monomer,
m/z 932 (calc), 932.6 (found); carboxyfluorescein-L-triskelion, m/z
3518.9 (calc), 3519.7 (found).
Analytical and semipreparative RP-HPLC was performed on a
JASCO HPLC system (PU-980; Tokyo, Japan), using Vydac C18
analytical and semipreparative (both 5 μm) columns. Both analytical
and semipreparative runs used a 10−70% B gradient over 30 min at 1
mL/min and 4.5 mL/min, respectively, with detection at 280 and 214
nm (buffer A, 5%, and buffer B, 95% aqueous CH3CN, 0.1% TFA).
Ψ-Capsid Assembly. Triskelions were assembled overnight at the
concentrations stated in the text (100−400 μM) in filtered (0.22 μm),
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10 mM MOPS, phosphate, or PBS buffers, pH 7.4, at room
temperature.
Circular Dichroism Spectroscopy. CD spectra were recorded
on a JASCO J-810 spectropolarimeter fitted with a Peltier
temperature controller. The measurements were taken in ellipticities
in mdeg and converted to molar ellipticities ([θ], deg cm2 dmol−1
res−1) by normalizing for the concentration of peptide bonds. The
data were collected with a 1 nm step, 1 s collection time per step, and
are presented as the average of 4 scans.
Fourier Transform Infrared Spectroscopy. FT-IR spectra were
recorded using a Tensor-27 series FTIR spectrometer equipped with a
BioATR II unit (Bruker Optics), as the sampling platform, and a
photovoltaic mercury cadmium telluride (MCT) detector and a
Bruker Optics workstation equipped with OPUS software. Low-
volume (20 μL) capsid samples (100 μM) were placed in a circular
sampling area of radius 2 mm with a path length of 6 μm. FT-IR
spectra was recorded with resolution 4 cm−1, scanner velocity 20 kHz,
256 scans, phase resolution 32, and zero filling factor 4. Spectra
deconvolutions were performed by Gaussian peak fitting using the
proprietary software.
Molecular Dynamics Simulations. MD simulations were
performed using the GROMACS 2016 software with the
GROMOS96 53A6 force field (atomistic) and the MARTINI force
field (coarse grain).32,33 An SPC water model was used for atomistic
simulations and standard MARTINI water for coarse grain
simulations. In all simulations chloride and sodium ions were added
up to a 150 mM concentration. Additional ions were placed if
required for charge neutralization. The initial Ψ-capsid configuration
was constructed geometrically using the editconf tool from
GROMACS. The DLPC/DLPG (3:1) membrane was constructed
with the PACKMOL software with dimensions of 12 × 12 nm
(atomistic) or 30 × 30 nm (coarse grain).43 Periodic boundary
conditions were imposed, setting the minimal distances between the
protein and the box boundaries to 3 nm. All simulations are run in the
NPT ensemble maintaining the temperature at 303 K with the
velocity rescale thermostat, and the pressure at 1 bar using the
Parrinello−Rahman barostat, with either an isotropic or semi-
isotropic coupling; simulations without and with membranes,
respectively. For atomistic simulations of the Ψ-capsid in solution,
multiple restrained equilibration runs (65 ns overall) precede 100 ns
productions, which were run in three replicates. Similarly, for coarse
grain simulations a 10 ns equilibration precedes 1 μs productions,
which were run in three replicates. For simulations including
membranes, the lipid patches were equilibrated for 500 ns (1 μs for
coarse grain) before placing the peptide close in contact with the lipid
surface (atomistic) or at the minimal distance of 1 nm (coarse grain).
Production was then carried out for 500 ns, and 10 μs for coarse grain.
Atomistic simulations with membranes were run with an electric field
of 130 mV/nm in the direction perpendicular to the membrane, with
the higher potential region on the side of the bilayer where the
peptide rests. Coarse grain MD modeling of double-walled Ψ-capsids
was performed using the PACKMOL software: the capsids were
constructed as two spherical cages, their radii defined by the number
of triskelions packed into a single bilayer with a hydrophobic
interface.43 The same, optimal packing of triskelions was used for all
the sizes.
Transmission Electron Microscopy. Micrographs of the Ψ-
capsids were recorded using a JEOL 1010 transmission electron
microscope equipped with an Orius SC1000 (Gatan Inc.) CCD
camera, operated at 80 keV. Droplets of capsid solution were placed
on glow-discharged Cu finder grids coated with carbon film (mesh
200) or holey carbon film with graphene oxide (mesh 300), stained
with uranyl acetate (aqueous 2%, w/v) for a few seconds, and buffer
excess was removed by blotting paper. Micrographs of E. coli were
recorded using a FEI Tecnai T12 transmission electron microscope
equipped with a Morada G2 (Olympus Inc.) camera, operated at 80
keV. Samples were fixed with glutaraldehyde (aqueous 5%, w/v),
treated with a postfixation agent osmium tetroxide (1%, w/v, 100 mM
PIPES, pH 7.2), and stained with uranyl acetate (aqueous 2%, w/v).
The resulting samples were embedded in a Spurr resin and were left
to solidify at 60 °C, over 24 h. The resin was then microtomed to
ultrathin sections, which were placed on Formvar carbon coated grids
(mesh 200), poststained using lead citrate (aqueous 5%, w/v), and
imaged.
Electron micrographs of MS2 bacteriophages were recorded using a
JEOL JEM1400-Plus transmission electron microscope equipped with
a OneView 4K (Gatan) camera, operated at 120 keV. Droplets of
phages in SM buffer (pH 7.5) were deposited on Formvar carbon
coated copper grids (mesh 200), stained with uranyl acetate (aqueous
1%, w/v) for 2 min, and blotted with a filter paper. The phages were
purchased from ATCC (Escherichia coli bacteriophage MS2, ATCC
15597-B1) and were cultured according to the proprietary protocols.
In-Liquid AFM and Peak Force QNM Imaging. Pseudocapsids
were assembled overnight at 100 μM in 10 mM MOPs, pH 7.4, room
temperature. A 50 μL sample of assembled solution was added to
freshly cleaved mica, prehydrated with 50 μL of imaging buffer (120
mM NaCl, 20 mM MOPs, pH 7.4). Imaging was performed using
PeakForce Tapping mode on a Multimode 8 AFM system (Bruker
AXS, USA) using MSNL-E cantilevers (Bruker AFM probes, USA)
and a 100 μL fluid cell (Bruker AXS, USA). Images were taken at a
PeakForce frequency of 2 kHz, PeakForce amplitude of 20 nm, and
PeakForce set-point of 10−30 mV (<100 pN). Both topography and
DMT modulus channels were recorded. Images were processed using
Gwyddion (http://gwyddion.net) for first-order line-by-line back-
ground subtraction (flattening), first-order plane fitting, and cross
correlation averaging.
Preparation of Unilamellar Phospholipid Vesicles for AFM
Imaging. 1,2-Dilauroyl-sn-glycero-3-phosphocholine (DLPC) with
1,2-dilauroyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DLPG) lipids
used for vesicle construction were from Avanti Polar Lipids
(Alabaster, AL, USA). DLPC was used as mammalian model
membranes, and DLPC/DLPG (3:1, molar ratios) was used as
bacterial model membranes. The lipids were weighted up, dissolved in
chloroform−methanol (2:1, vol/vol), and dried under a nitrogen
stream and then under vacuum to form a thin film. The film was
hydrated in 10 mM phosphate buffer (pH 7.2) with shaking (1 h, 220
rpm) and bath sonicated for 30 min. The obtained suspension was
extruded using a hand-held extruder (Avanti Polar lipids) (29 times,
polycarbonate filter, 0.05 μm) to give a clear solution of small
unilamellar vesicles, the sizes of which (50 nm) were confirmed by
photon correlation spectroscopy.
In-Liquid AFM on Supported Lipid Bilayers. Supported lipid
bilayers were formed using a vesicle fusion method as described
elsewhere.42 Freshly prepared vesicles (1.5 μL, 3 mg/mL) were added
to cleaved mica prehydrated with buffer (70 μL, 120 mM NaCl, 20
mM MOPS, 20 mMMgCl2). Following adsorption and incubation for
45 min, the samples were washed to remove unfused vesicles, and
resulting SLBs were checked to confirm they were defect free.
Peptides were then introduced into a 100 μL fluid cell (Bruker AXS,
USA), where they were diluted to the final concentrations of 0.1−0.8
μM. All imaging was performed using PeakForce Tapping mode on a
Multimode 8 AFM system (Bruker AXS, USA) using MSNL-E
cantilevers (Bruker AFM probes, USA). Images were taken at a
PeakForce frequency of 2 kHz, PeakForce amplitude of 10 nm, and
PeakForce set-point of 10−30 mV (<100 pN). Images were processed
using Nanoscope analysis software (Bruker AXS, USA) or Gwyddion
(http://gwyddion.net) for first-order line-by-line background sub-
traction (flattening) and first-order plane fitting.
Photon Correlation Spectroscopy. Prepared phospholipid
vesicles for AFM imaging were resuspended to a final concentration
of 1 mg/mL and were analyzed on a Zetasizer Nano (ZEN3600;
Malvern Instruments). Dynamic light scattering batch measurements
were carried out in a low-volume disposable cuvette at 25 °C.
Hydrodynamic radii were obtained through the fitting of autocorre-
lation data using the manufacturer’s Dispersion Technology Software
(version 5.10).
Minimum Inhibitory Concentrations Assay. Minimum inhib-
itory concentrations were determined by broth microdilution on P.
aeruginosa, E. coli, S. aureus, M. luteus, B. subtilis, S. typhimurium, and
K. pneumoniae according to the Clinical and Laboratory Standards
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Institute. Typically, 100 μL of (0.5−1) × 106 CFU per mL of each
bacterium in Mueller Hinton media broth (Oxoid) was incubated in
96-well microtiter plates with 100 μL of serial 2-fold dilutions of the
capsids (from 100 to 0 μM) at 37 °C on a 3D orbital shaker. The
absorbance was measured after capsid addition at 600 nm using a
SpectraMax i3x Multi-Mode microplate reader (Molecular Devices).
MICs were defined as the lowest peptide concentration that inhibited
visible bacterial growth after 24 h at 37 °C. All tests were done at least
in triplicate, and results are summarized in Table S1. The values that
are given without standard deviations are those for which no
variations were found within triplicates.
Hemolysis Assay. Hemolysis was determined using human
erythrocytes sourced commercially from Cambridge Bioscience Ltd.
and used within 2 days; 10% (v/v) suspensions of human erythrocytes
were incubated with the capsids. The cells were rinsed four times in
10 mM phosphate buffer saline (PBS, Gibco), pH 7.2, by repeated
centrifugation and resuspension (3 min at 3000g). The cells were then
incubated at room temperature for 1 h in either deionized water (fully
hemolysed control), in PBS, or with capsid in PBS. After
centrifugation at 10000g for 5 min, the supernatant was separated
from the pellet, and the absorbance was measured at 550 nm using a
SpectraMax i3x Multi-Mode microplate reader (Molecular Devices).
Absorbance of the suspension treated with deionized water defined
complete hemolysis. All tests were done in triplicate, and results are
shown in Table S1. The values given correspond to concentrations
needed to kill half of the sample population (50% lysis of
erythrocytes) and are expressed as median lethal concentrations,
LC50.
Bacterial Culture for Single-Cell Antimicrobial Kinetics
Measurements. Lysogeny broth (LB) (10 g/L tryptone, 5 g/L
yeast extract, and 0.5 g/L NaCl, Formedium) and LB agar plates (LB
with 15 g/L agar) were used for planktonic and plate bacteria growth,
respectively. E. coli BW25113 was purchased from Dharmacon (GE
Healthcare). Single colonies were picked from a streak plate and were
incubated at 37 °C, over 17 h in fresh LB medium (100 mL) with
shaking (200 rpm). The prepared culture was spun down (10 min,
3000g, and 20 °C). The supernatant was filtered twice (Medical
Millex-GS filter, 0.22 μm, Millipore Corp.) and used to resuspend the
bacteria pellet to an OD595 of 50. The resulting highly concentrated
bacterial suspension was used in high-throughput single-cell kinetic
measurements, together with M9 minimal medium (7 g/L Na2HPO4,
3 g/L KH2PO4, 1 g/L NH4Cl, 0.5 g/L NaCl, 1 mM thiamine
hydrochloride) (Sigma-Aldrich), ampicillin (Sigma-Aldrich), and
propidium iodide (PI) (Thermo Fisher Scientific), as described
below.
High-Throughput Single-Cell Kinetic Measurements. Anti-
microbial efficacy with a single-cell resolution was measured using a
multichannel microfluidics device as reported elsewhere.44,45 The
device used was a polydimethylsiloxane (PDMS, Dow Corning)
replica of the original mold kindly provided by Suckjoon Jun.44 The
device is an array of dead-end microfluidic channels 1.5 μm in
diameter and 25 μm in length. Each channel can host 1−4 bacterial
cells in a single file. The channels are connected to a main
microchamber (25 × 100 μm) that is continuously supplied with
antimicrobial agents, fresh LB, or PI (see below). The device was
permanently attached to a glass coverslip and functionalized with a
solution of bovine serum albumin (50 mg/mL). A 2 μL amount of the
highly concentrated bacterial suspension, prepared as described
above, was injected in the device, and individual bacteria were
allowed to diffuse into the lateral channels for 30 min. The device was
then completed with fluorinated ethylene propylene inlet and outlet
tubing (1/32 in. × 0.008 in.) connected to a flow-rate measuring
system (Flow Unit S, Fluigent, France) with the applied pressure
controlled by a computerized pressure-based flow control system
(MFCS-4C, Fluigent). The completed device was mounted on an
inverted microscope (IX73 Olympus, Tokyo, Japan) equipped with a
60×, 1.2 NA objective (UPLSAPO60XW, Olympus) and an sCMOS
camera (Zyla 4.2, Andor, Belfast, UK) used to acquire bright-field
images (exposure time 0.03 s) of a thousand channels per hour for the
duration of each experiment (24 h). After acquiring the first set of
images, the microfluidic environment was changed by flowing M9−
LB (9:1 v/v) containing antimicrobial agents (D/Ψ-capsids or
ampicillin) at 25 × MIC at 100 μL/h over 3 h and then by LB for
a further 21 h. At 24 h PI (30 μM) was delivered into the microfluidic
device for 10 min to identify dead cells with compromised cell
membranes. The device allowed tracking each bacterial cell and its
progeny throughout the assay, with the images obtained in each
channel loaded to ImageJ.
Time-Lapse Structured Illumination Microscopy of E. coli
and S. aureus. Bacteria (E. coli ATCC 15597 and S. aureus ATCC
6538) were inoculated into Mueller Hinton broth, grown overnight at
37 °C and 150 rpm, reinoculated, and grown to an OD600 of 0.5−0.8.
The cells were then pelleted by centrifugation (4000 rpm, 10 min)
and, after removing the supernatant, were resuspended in 1 mL of
PBS (10 mM) and transferred to an Eppendorf tube. FM4-64 (1 mg/
mL, 5 μL) was added to each tube followed by rotation on a rotating
disk for 5 min. The cells were then centrifuged (7000 rpm, 3 min), the
supernatant was removed, and the cell pellet was resuspended in PBS
(1 mL). Bacteria was then diluted to an OD600 of 0.16 and 0.08 for E.
coli and S. aureus, respectively. A 100 μL amount of each suspension
was added to different wells of a chambered microscope coverslip
(Ibidi μ-Slide 8 well) and left for 30 min to allow cells to settle onto
the substrate. Immediately prior to each imaging experiment a 100 μL
solution of Ψ-capsids assembled from carboxyfluorescein-labeled and
unlabeled triskelions at 1:100 molar ratios was added to the well to a
final concentration of 50 μM (total peptide). For control data sets,
100 μL of PBS was added prior to imaging. Time lapse imaging was
performed at 5 min intervals using a custom-built structured
illumination microscope.54 Briefly, sinusoidal excitation patterns
were generated by projecting a spatially filtered image of a spatial
light modulator (SLM), configured to display a series of binary phase
gratings, into the focal plane of the microscope objective lens
(UPLSAPO 60×/1.3, Olympus). Sample images were acquired using
a scientific CMOS camera (ORCA-Flash4.0, Hamamatsu Photonics),
with the global exposure period of the camera’s rolling shutter
synchronized to the pattern displayed on the SLM. At each time point
FM4-64 and carboxyfluorescein-labeled capsids were imaged sequen-
tially, using excitation at 561 nm with a 655 nm long-pass emission
filter and excitation at 488 nm with a 525/50 bandpass emission filter,
respectively. Images were reconstructed as described elsewhere,55 and
lateral drift and chromatic offsets in the reconstructed images were
corrected using ImageJ. The FM4-64 color channel was then
corrected for photobleaching using an exponential fit to the image
intensity within a suitable region of interest. Manual background
subtraction and color balancing were performed to optimize image
contrast.
In Vivo MRSA Clearance Assay. The Galleria mellonella larvae
assay was performed as described elsewhere.57,58 Wax moth larvae
were purchased in bulk from Livefood UK, stored at 4 °C upon
arrival, and kept at 37 °C during the course of the assay. Ψ-Capsid
samples were prepared from stock solutions in Milli-Q water to
working concentrations in sterile PBS. Typically, a single bacterial
colony was picked to inoculate 5 mL of tryptic soy broth (TSB), and
the resulting culture was left to grow overnight (∼16 h) at 37 °C with
shaking (200 rpm). The culture was then diluted (100×) into fresh
TSB (5 mL) and incubated over 4 h at 37 °C with shaking (200 rpm).
After centrifugation (2500g) for 10 min, pellets were obtained and
resuspended in sterile PBS to an OD595 of 0.2, giving ∼108 CFU/mL.
The resuspended culture (10 μL aliquots; ∼1.2 × 106 CFU) was
administered to larvae (seven groups; n = 10 in each group) behind
the rear thoracic segments using a Tridak stepper pipette dispenser
(Dymax, UK). The infected larvae were then treated by injection with
10 μL of L/Ψ-capsid (12.5 μM), D/Ψ-capsid, (12.5 μM), magainin 2
(12.5 μM), cecropin B (12.5 μM), LL37 (12.5 μM), vancomycin (40
μM), or PBS at stated time points after inoculation. The toxicity of Ψ-
capsid was assessed using two groups of larvae (n = 10 in each group).
These were mock-infected with PBS and treated with 10 μL of L or D/
Ψ-capsid (25 μM) at stated time points after inoculation. For the
delayed treatment assay, three groups of infected larvae (∼106 CFU)
were treated with 10 μL of L/Ψ-capsid (12.5 μM), vancomycin (40
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μM), or PBS at stated time points after inoculation. All experiments
were carried out as blind studies, and the treatment identities were
not revealed until each experiment was completed. Larvae were
considered dead when they did not respond to touch to the head.
Survival curves were generated and analyzed using GraphPad Prism 6
software.
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